Results 31 to 40 of about 3,632,283 (294)

Bladder Cancer [PDF]

Journal of the National Comprehensive Cancer Network, 2013
Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non-muscle-invasive and muscle-invasive urothelial carcinoma of ...
Peter E, Clark, Neeraj, Agarwal, Matthew C, Biagioli, Mario A, Eisenberger, Richard E, Greenberg, Harry W, Herr, Brant A, Inman, Deborah A, Kuban, Timothy M, Kuzel, Subodh M, Lele, Jeff, Michalski, Lance C, Pagliaro, Sumanta K, Pal, Anthony, Patterson, Elizabeth R, Plimack, Kamal S, Pohar, Michael P, Porter, Jerome P, Richie, Wade J, Sexton, William U, Shipley, Eric J, Small, Philippe E, Spiess, Donald L, Trump, Geoffrey, Wile, Timothy G, Wilson, Mary, Dwyer, Maria, Ho   +26 more
openaire   +2 more sources

The Value of Negative Urinary Dipstick Tests for Haematuria in Patients Undergoing Surveillance for Low-grade Ta Urothelial Cancer: A Two-stage Prospective Clinical Study in 524 Patients

European Urology Open Science
Background and objective: The risk of first recurrence beyond 5 yr for patients with low-grade (LG) Ta non–muscle-invasive bladder cancer (NMIBC) is low enough to consider discontinuing cystoscopic surveillance at that point.
Chandrarajan Premal Shah, Tanya Lord-McKenzie, Antonios Makris, Matthew Trail, Jennifer Gray, Gordon Smith, Paramananthan Mariappan   +6 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Measurements of complement factor H-related protein (BTA-TRAK (TM) assay) and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary bladder cancer? [PDF]

, 2003
Between 1997 and 2000 we investigated in a prospective study the voided urine samples of all consecutive patients undergoing cystoscopy independent from their clinical background (n=705) with the BTA-TRAK(TM) assay (Bard Diagnostics, Redmont, USA ...
Holdenrieder, Stefan, Stephan Tauber, Karin Hofmann, Reiter, Wolfgang, Brigitte Mahnert, Dorothea Nagel, Hofmann, Karin, Mahnert, Brigitte, Stieber, Petra, Tauber, Stephan, Kriegmair, Martin, Martin Kriegmair, Nikolaus Schmeller, Stefan Holdenrieder, Schmeller, Nikolaus, Wolfgang Reiter, Nagel, Dorothea, Petra Stieber   +17 more
core   +2 more sources

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection

Biomarker Research
Background and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear which type of
Naheema S. Gordon, Elspeth K. McGuigan, Michaela Ondasova, Jennifer Knight, Laura A. Baxter, Sascha Ott, Robert K. Hastings, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Anshita Goel, Minghao Yu, Roland Arnold, Richard T. Bryan, Douglas G. Ward   +14 more
doaj   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression

Bladder Cancer
Background The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity.
Jessica L Neil, Naheema S Gordon, Anshita Goel, Ayse N Myumyun, Benjamin Tura, Joep J de Jong, Elai Davicioni, Maurice P Zeegers, Kar Keung Cheng, Nicholas D James, Mario Neou, Roland Arnold, Richard T Bryan, Douglas G Ward   +13 more
doaj   +1 more source

CANCER OF THE BLADDER [PDF]

Journal of the American Medical Association, 1912
A year ago I published an account of an early case of carcinoma of the bladder which Dr. Chute and I removed by the transperitoneal route. The so far successful outcome of this case has encouraged me to present a brief summary of this condition in order to bring up several points for discussion in regard to cancer of the bladder; also to endeavor to ...
openaire   +1 more source